Speaking at AAO 2019, Ashraf El Habbak MD, PhD pointed out that bevacizumab inhibits vascular endothelial growth factor, which is a potent permeability factor implicated in cystoid macular edema.
Cheryl Guttman Krader
According to William D. Trattler, MD, surgeons today can choose from a number of newer modalities that address the drawbacks associated with previous options.
According to Jeffrey Heier, MD, RGX-314 administered by subretinal injection was well tolerated. In addition, it was associated with dose-dependent increase in ocular protein expression and evidence of clinical benefit.
Nieraj Jain, MD, describes the investigations that led to the recent identification of this drug-related retinal toxicity and described the clinical features that support its diagnosis.
Speakers at AAO 2019 event describe journey leading to approval of the first gene therapy for a genetic disease.
The 10-year survival rate for patients with hereditary retinoblastoma is excellent, but these individuals are at increased risk for developing secondary cancers and have elevated mortality compared to age-matched individuals in the genera
Researchers demonstrate the feasibility of a surgical method that specifically targets the area of geographic atrophy for RPE replacement.
The transzonular injection of a corticosteroid and fluoroquinolone can prevent postoperative infection and inflammation.
Phase III studies of a gene therapy for Leber Hereditary Optic Neuropathy have generated some unexpected positive findings. There is biologic plausibility to explain the data.
Tools for higher-order OCT assessment enable evaluation of features of interest, such as targeted retinal layers or fluid compartments, and may allow for unique characterization of disease phenotypes and treatment response.